Be the first to know
Subscribe here to receive NVM email bulletins about NVM, our market and our portfolio straight to your inbox.
DxS was launched in 2001 based on a highly innovative genotyping platform developed by the founders Dr Steve Little and Dr David Whitcombe.
Personalised medicine technology allowing treatment to be tailored to individual patients.
DxS was sold to QIAGEN NV for £82m representing 13 times money.
DxS secured a first mover advantage by positioning its technology as the key to the successful launch of five therapies by global pharmaceutical companies.
The opportunity arose following the merger of Astra and Zeneca when the founders were given the opportunity to spin out the intellectual property from the diagnostics division in which they worked. Their vision was to create a world-leading diagnostics company to capitalise on anticipated regulation and market trends towards personalised medicine. Their technology helps to predict drug response in individual patients and change the way in which drugs are prescribed as a result.
NVM provided several further funding rounds since its original investment in 2001. However, it all paid off in 2009 following rapid sales growth after DxS launched their first to market with a predictive test (known as a “companion diagnostic’) for a block-buster colorectal cancer therapy. Market interest in DxS immediately became intense and several multinational pharmaceutical companies signed up with DxS to develop further companion diagnostics.
At this point NVM appointed pharmaceutical industry heavyweight Ron Long as Chairman of the Board, who played a pivotal role in delivering the exit. The sale of DxS to QIAGEN NV has enabled the company to consolidate its position as global leader in its field.
Dr. Steve Little, CEO of DxS